*3.1. Study Flow*

Records of 46 patients were identified for review, of which 11 were included in the study. Figure 1 shows the number of patients successively meeting each of the eligibility criteria. Complete data were collected for all 11 patients included in the study. *Brain Sci.* **2021**, *11*, x FOR PEER REVIEW 5 of 13

**Figure 1.** Flow diagram of identification of patients in the study. SSRI: selective serotonin reuptake inhibitor. Mild 2 (18%) **Figure 1.** Flow diagram of identification of patients in the study. SSRI: selective serotonin reuptake inhibitor.

**Eligible for Inclusion** *n* **= 11**

were White. Age ranged from 18 to 46 years. Three (27%) had a comorbid psychiatric diagnosis in addition to the depressive disorder, and all had one or more comorbid medical diagnoses. Five (45%) had a history of treatment with any psychiatric medication, and

**Table 1.** Demographic and Clinical Characteristics of Patients at the Time of SSRI Initiation.

Female 4 (36%) Male 7 (64%) Age, mean (SD; range in years) 27.2 (7.7; 18–46)

White 10 (91%) Other 1 (9%)

Any intellectual disability 11 (100%)

*3.2. Demographic and Clinical Characteristics of the Sample*

three (27%) had a history of treatment with an SSRI.

Sex, *n* (%)

Race <sup>1</sup>

, *n* (%)

Intellectual Disability, *n* (%)
